in image illustration of covaxin
A study was conducted by the Coronavirus vaccine-induced antibody titer (COVAT), and it has been found that the seropositivity rates and median anti- spike antibody titer were notably higher in Astra Zeneca's covishield as compared to Bharat biotech's covaxin.
This study was conducted on 515 health workers in India who have received both doses of either of the two Covid vaccines, which were approved in January 2021. Out of the 552 workers, 95.0 percent showed seropositivity after two doses of both vaccines.
Significantly, both the vaccines( covaxin and covishield) showed a good immune system after the completion of the two doses.
Among the 552 healthcare workers, 325 were male, and 227 were female.456 received the covishield, and 96 received the covaxin vaccine. Overall, 79.3 percent showed seropositivity after their first shot.
Compared to covaxin, covishield has a higher responder and median( IQR) rise in anti-spike antibody.
In January 2021, the Oxford- Astra Zenecas covishield and Bharat biotech's covaxin manufactured by the Serum Institute of India was approved for the emergency use authorization by the DCGI-CDSCO.
The Serum institute provides the covishield dose for Rs.600 to private hospitals and Rs.300 to the state government.
NCB regional director Sameer Wankhede is not targeting Bollywood, his wife Kranti Redkar told India Today on Monday. He also responded to the allegati...
Union Home Secretary Amit Shah, who is on a three-day visit to Jammu and Kashmir, on Sunday inaugurated a new campus at the Indian Institute of Techno...